STOCK TITAN

Equity grants to REGENXBIO (NASDAQ: RGNX) director Jean Bennett

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

REGENXBIO Inc. director Jean Bennett received new equity awards as part of compensation. She was granted 9,807 shares of common stock in the form of a time-based restricted stock unit (RSU) award, bringing her total direct holdings to 28,861 common shares.

She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share. Both the RSU and the option award are scheduled to vest on May 29, 2027, subject to her continuous service with REGENXBIO. The options expire on May 29, 2036.

Positive

  • None.

Negative

  • None.
Insider Bennett Jean
Role null
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 46,600 $0.00 --
Grant/Award Common Stock 9,807 $0.00 --
Holdings After Transaction: Stock Options (Right to Buy) — 46,600 shares (Direct, null); Common Stock — 28,861 shares (Direct, null)
Footnotes (1)
  1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
RSU shares granted 9,807 shares Time-based restricted stock unit award to director Jean Bennett
Options granted 46,600 options Stock options (right to buy) underlying common stock
Option exercise price $7.01 per share Strike price for 46,600 stock options
Shares held after grant 28,861 shares Total direct common stock holdings following RSU award
Vesting date May 29, 2027 Vesting for both RSU and stock option awards
Option expiration May 29, 2036 Expiration date for 46,600 stock options
restricted stock unit financial
"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of 7.0100."
exercise price financial
"conversion_or_exercise_price: "7.0100" for the stock options grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The option will vest on May 29, 2027 and has an expiration date of May 29, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bennett Jean

(Last)(First)(Middle)
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026A9,807(1)A$0.0028,861D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$7.0105/29/2026A46,60005/29/2027(2)05/29/2036Common Stock46,600$0.0046,600D
Explanation of Responses:
1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Remarks:
/s/ Patrick J. Christmas as attorney-in-fact06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did REGENXBIO (RGNX) director Jean Bennett receive?

Jean Bennett received a grant of 9,807 common shares via a restricted stock unit award and stock options on 46,600 shares. These awards represent compensation rather than open-market purchases and are tied to continued service with REGENXBIO.

What are the vesting terms of Jean Bennett’s new REGENXBIO (RGNX) RSUs?

The 9,807-share restricted stock unit award vests 100% on May 29, 2027, if Jean Bennett continues serving REGENXBIO until that date. Until vesting, the RSUs represent a right to receive shares rather than currently issued, unrestricted stock.

What are the key terms of Jean Bennett’s new REGENXBIO (RGNX) stock options?

Jean Bennett was granted options on 46,600 REGENXBIO common shares at an exercise price of $7.01 per share. These options vest on May 29, 2027, subject to continuous service, and expire on May 29, 2036, if not exercised earlier.

How many REGENXBIO (RGNX) common shares does Jean Bennett hold after these awards?

Following the RSU grant, Jean Bennett directly holds 28,861 REGENXBIO common shares. This total includes the newly awarded 9,807-share restricted stock unit grant reported in the filing as common stock underlying the RSU award.

Are Jean Bennett’s recent REGENXBIO (RGNX) transactions open-market buys or sales?

The transactions are equity compensation awards, not open-market trades. They consist of a restricted stock unit grant for 9,807 shares and stock options for 46,600 shares, both awarded at no cash cost to her on the grant date.